Investment case
Armata Pharmaceuticals Inc.
ARMP · 2 developments mapped · last assessed 2026-09-23
Market Ontology has mapped 2 macro, policy, and market developments to Armata Pharmaceuticals Inc. since 2026-09-14. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for ARMP yet, so no modelled value is shown. The ARMP valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run ARMP on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Regulatory milestone achievement, de-risking of clinical development, enhanced market perception, potential for accelerated approval pathway.
· Moves probability of success for ap sa02, time to market for ap sa02, peak sales estimates for ap sa02
What changed, by assumption
- 2026-09-14Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
- 2026-09-23Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-09-23 | Cost of capital | Bearish | IG cost of debt is below blended cost of capital; weighting effect lowers WACC. | 0.70 |
| 2026-09-23 | Interest expense | Bullish | New IG coupon adds to recurring interest expense. | 0.70 |
| 2026-09-23 | Net debt | Bullish | Investment-grade issuance adds gross debt to the balance sheet. | 0.70 |
| 2026-08-15 | Net debt | Bullish | Funding of a $25 million term loan increases the company's total debt obligations. | 0.90 |
| 2026-08-15 | Share count | Bullish | Issuance of shares via ATM program and stock option exercises increases total shares outstanding. | 0.90 |
| 2026-08-15 | Cost of capital | Bullish | Higher cost-of-debt tranche lifts blended WACC. | 0.70 |
| 2026-08-15 | Interest expense | Bullish | High-yield coupon materially raises interest burden. | 0.70 |
| 2026-08-15 | Net debt | Bullish | Sub-IG debt raise increases leverage and net debt. | 0.70 |
| 2026-08-15 | Valuation multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. | 0.70 |
| 2026-08-15 | Share count | Bullish | Primary equity issuance increases diluted share count. | 0.70 |
| 2026-07-20 | Net debt | Bearish | Liability-management transactions often reduce gross debt or push maturities out. | 0.70 |
| 2026-07-20 | Interest expense | Bearish | Tender/exchange extends maturity profile and typically lowers near-term interest expense. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-23 | Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War | Bullish | 1-3m | 0.70 |
| 2026-09-14 | Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 | Bullish | 1-3m | 0.90 |